Analyzing heart failure with preserved ejection fraction in Chinese Han patients
Cohort Study of Heart Failure With Preserved Ejection Fraction in Chinese Han
This study looks at what causes heart failure with preserved ejection fraction in older Chinese Han patients to see how we can better treat and prevent it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT05278026 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to analyze the factors contributing to the development and prognosis of heart failure with preserved ejection fraction (HFpEF) specifically in Chinese Han patients. It focuses on evaluating various exposures and risk factors associated with HFpEF in individuals with cardiovascular diseases. Given the increasing prevalence of HFpEF in the aging population of China, the study seeks to identify preventive and therapeutic targets that could improve patient outcomes. The research will utilize guideline-recommended routine treatments for participants.
Who should consider this trial
Good fit: Ideal candidates for this study are Chinese Han patients diagnosed with cardiovascular diseases such as coronary heart disease, hypertension, type 2 diabetes, or cardiomyopathy.
Not a fit: Patients with primary diagnoses of atherosclerosis or congenital heart diseases may not receive benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prevention and treatment strategies for heart failure with preserved ejection fraction in Chinese patients.
How similar studies have performed: Other studies have shown success in identifying risk factors for heart failure, but this specific focus on the Chinese Han population may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with CVD, defined as at least one diagnosis of coronary heart disease, hypertension, type 2 diabetes or cardiomyopathy. The definition of coronary heart disease was stenosis of the main coronary arteries ≥ 50% using percutaneous coronary angiography or coronary computed tomography angiography findings. The definition of hypertension was systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or pharmacological treatment. The definition of type 2 diabetes was fasting blood glucose ≥ 7.0 mmol/L, random blood glucose ≥ 11.1 mmol/L and HbA1c \> 6.5% or the or the use of hypoglycaemic medications. Cardiomyopathy was defined as the presence of cardiac insufficiency in patients with dilated cardiomyopathy suggested by percutaneous coronary angiography or coronary CT angiography use of hypoglycaemic medications. Exclusion Criteria: * primary diagnoses of atherosclerosis (stenosis of the main coronary arteries \< 50%), congenital heart diseases, arrhythmia, lung diseases, aortic dissection, peripheral vascular diseases, pericardial diseases, myocarditis, hypertrophic cardiomyopathy, heart valvular diseases, cardiophobia, costal chondritis, shock, thyroid diseases, infection or concomitant liver or renal dysfunction.
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Junxia Zhang, MD
- Email: zhangjunshia@njmu.edu.cn
- Phone: 15366155682
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.